Literature DB >> 7686211

Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma.

A Stoppacciaro1, C Melani, M Parenza, A Mastracchio, C Bassi, C Baroni, G Parmiani, M P Colombo.   

Abstract

Using the murine colon adenocarcinoma C-26 cell line, engineered to release granulocyte colony-stimulating factor (G-CSF) (C-26/G-CSF), were studied the mechanisms responsible for inhibition of tumor take in syngeneic animals and of regression of an established tumor in sublethally irradiated mice injected with these cells. Immunocytochemistry and in situ hybridization, performed to characterize tumor-infiltrating leukocytes and their cytokine expression, respectively, indicated that polymorphonuclear leukocytes (PMN) were the major cells responsible for inhibition of tumor take and that they expressed mRNA for interleukin 1 alpha (IL-1 alpha), IL-1 beta, and tumor necrosis factor alpha (TNF-alpha). Expression of interferon gamma (IFN-gamma) and of IL-4 was undetectable, consistent with the absence of T lymphocytes at the site of tumor injection. In mice injected with C-26/G-CSF cells after 600-rad irradiation, the tumors grew to approximately 1.5 cm in 30 d, regressing completely thereafter in 70-80% of mice. During the growing phase, tumors were infiltrated first by PMN (between days 15 and 20), then by macrophages, and last by T lymphocytes. Both CD4+ and CD8+ T cells were present but only CD8 depletion significantly abrogated tumor regression. Depletion of PMN by the RB6-8C5 antigranulocytes monoclonal antibody reduced the number of T cells infiltrating the tumor and prevented tumor regression. In situ hybridization performed at the beginning of tumor regression revealed the presence of mRNA for IL-1 alpha, IL-1 beta, and TNF-alpha, but also the presence of cells, with lymphoid morphology, expressing IFN-gamma. Tumors from mice treated with recombinant IFN-gamma (between days 20 and 35) were rejected faster, whereas mice treated with antibodies to IFN-gamma (from day 20) died of progressive tumor. Cyclosporin A treatment (started at day 20) also abrogated tumor regression. These results indicate that inhibition of tumor take and regression in this model occurs through different mechanisms that involve PMN and PMN-T cell interactions, respectively, as well as a combination of cytokines that, for tumor regression, require IFN-gamma. Thus, gene transfer of a single cytokine gene such as G-CSF into tumor cells appears to be sufficient to trigger the cascade of cell interactions and cytokine production necessary to destroy a cancer nodule.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7686211      PMCID: PMC2191097          DOI: 10.1084/jem.178.1.151

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  34 in total

Review 1.  Cytokine regulation of endothelial cell function.

Authors:  A Mantovani; F Bussolino; E Dejana
Journal:  FASEB J       Date:  1992-05       Impact factor: 5.191

2.  An eosinophil-dependent mechanism for the antitumor effect of interleukin-4.

Authors:  R I Tepper; R L Coffman; P Leder
Journal:  Science       Date:  1992-07-24       Impact factor: 47.728

3.  Expression of interleukin-1 alpha and beta genes by human blood polymorphonuclear leukocytes.

Authors:  P C Lord; L M Wilmoth; S B Mizel; C E McCall
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

4.  Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity.

Authors:  W H McBride; J D Thacker; S Comora; J S Economou; D Kelley; D Hogge; S M Dubinett; G J Dougherty
Journal:  Cancer Res       Date:  1992-07-15       Impact factor: 12.701

5.  Eosinophil as antigen-presenting cell: activation of T cell clones and T cell hybridoma by eosinophils after antigen processing.

Authors:  V Del Pozo; B De Andrés; E Martín; B Cárdaba; J C Fernández; S Gallardo; P Tramón; F Leyva-Cobian; P Palomino; C Lahoz
Journal:  Eur J Immunol       Date:  1992-07       Impact factor: 5.532

6.  Granulocyte colony-stimulating factor (G-CSF) gene transduction in murine adenocarcinoma drives neutrophil-mediated tumor inhibition in vivo. Neutrophils discriminate between G-CSF-producing and G-CSF-nonproducing tumor cells.

Authors:  M P Colombo; L Lombardi; A Stoppacciaro; C Melani; M Parenza; B Bottazzi; G Parmiani
Journal:  J Immunol       Date:  1992-07-01       Impact factor: 5.422

Review 7.  Cytokines and cancer: experimental systems.

Authors:  T Blankenstein; D A Rowley; H Schreiber
Journal:  Curr Opin Immunol       Date:  1991-10       Impact factor: 7.486

8.  Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer.

Authors:  T Blankenstein; Z H Qin; K Uberla; W Müller; H Rosen; H D Volk; T Diamantstein
Journal:  J Exp Med       Date:  1991-05-01       Impact factor: 14.307

9.  Interleukin 7 induces CD4+ T cell-dependent tumor rejection.

Authors:  H Hock; M Dorsch; T Diamantstein; T Blankenstein
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

10.  Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells.

Authors:  S Singh; S R Ross; M Acena; D A Rowley; H Schreiber
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

View more
  52 in total

1.  Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response.

Authors:  C Chiodoni; P Paglia; A Stoppacciaro; M Rodolfo; M Parenza; M P Colombo
Journal:  J Exp Med       Date:  1999-07-05       Impact factor: 14.307

Review 2.  Transgenic mice in the study of cytokine function.

Authors:  J Taverne
Journal:  Int J Exp Pathol       Date:  1993-12       Impact factor: 1.925

Review 3.  Immunotherapy I: Cyclosine gene transfer strategies.

Authors:  M P Colombo; G Forni
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

Review 4.  Immunotherapy III: Combinatorial molecular immunotherapy--a synthesis and suggestions.

Authors:  R G Vile; H Chong
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

Review 5.  Gene therapy in pediatric oncology.

Authors:  E Benaim; B P Sorrentino
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 6.  Protumor and antitumor functions of neutrophil granulocytes.

Authors:  Sven Brandau; Claudia A Dumitru; Stephan Lang
Journal:  Semin Immunopathol       Date:  2012-09-25       Impact factor: 9.623

7.  Multiple effects of transfection with interleukin 2 and/or interferon gamma on the behavior of mouse T lymphoma cells.

Authors:  A B Geldhof; J Van Ginderachter; P Vandersteen; G Raes; P De Baetselier
Journal:  Clin Exp Metastasis       Date:  1998-07       Impact factor: 5.150

8.  Combination gene therapy for liver metastasis of colon carcinoma in vivo.

Authors:  S H Chen; X H Chen; Y Wang; K Kosai; M J Finegold; S S Rich; S L Woo
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

Review 9.  The dual role of complement in cancer and its implication in anti-tumor therapy.

Authors:  Ioannis Kourtzelis; Stavros Rafail
Journal:  Ann Transl Med       Date:  2016-07

Review 10.  Enhancement of anti-tumor immunity by photodynamic therapy.

Authors:  Sandra O Gollnick; Craig M Brackett
Journal:  Immunol Res       Date:  2010-03       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.